Inflexion kicks off Rosemont Pharmaceuticals sale

Rosemont is being marketed off a run-rate EBITDA of GBP 55m and FY23 adjusted EBITDA of GBP 51m, the sources said. Information memoranda are out, one said, with the other adding that the sellside is receiving feedback from lenders.

Sellside advisor Evercore ran management presentations in the second week of May, one of the sources said. Non-binding offers are due in around four weeks' time, the other said.

On the equity side, Blackstone has looked at the asset ahead of non-binding offers, alongside US pharma and traditional buyout firms, one said. Other strategic suitors are also expected to participate in the auction, the other said.

At least one of the lenders passed due to a concentrated product offering, one of the sources said, adding that one drug accounts for just more than a quarter of the company's sales, which could decline in price and volume when a competitor arises.

Inflexion declined to comment. Evercore and Blackstone did not respond to requests for comment.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• Healthcare
• UK / Ireland
• Mergermarket
• Inflexion Private Equity
• United Kingdom